Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin type A - AbbVie

Next Previous
Drug Profile

Botulinum toxin type A - AbbVie

Alternative Names: AGN-151607

Latest Information Update: 29 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer AbbVie
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 29 Nov 2023 Discontinued - Phase-II for Atrial fibrillation (Prevention) in Germany, United Kingdom, Canada, Italy, Sweden, Netherlands, Austria, Spain, USA (Intracardiac) (AbbVie pipeline, November 2023)
  • 11 Nov 2023 Efficacy and adverse events data from a phase II NOVA trial in Atrial fibrillation presented at the American Heart Association Scientific Sessions (AHA-2023)
  • 11 Nov 2023 Pharmacodynamics data from a phase II NOVA trial in Atrial fibrillation presented at the American Heart Association Scientific Sessions (AHA-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top